FDA Approves Zytiga Plus Prednisone for Metastatic High-Risk Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson on February 8, 2018, announced U.S. Food and Drug Administration (FDA) approval of a new indication for Zytiga (abiraterone acetate) in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC). 

Read Corporate Press Release
Posted 2/8/18